Sandbox Reserved 712: Difference between revisions
From Proteopedia
Jump to navigationJump to search
| Line 24: | Line 24: | ||
<references/> | <references/> | ||
(1) Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. F. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690. | (1) Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. F. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690. | ||
(2) Watkins T, Resch W, Irlbeck D, Swanstrom R (February 2003). "Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors". Antimicrob. Agents Chemother. 47 (2): 759–69. doi:10.1128/AAC.47.2.759-769.2003. PMC 151730. PMID 12543689. | |||
== '''Contributors''' == | == '''Contributors''' == | ||
Julia Baaske, Angelika Wackerl | Julia Baaske, Angelika Wackerl | ||
